Smoking as a Chronic Disease
- First Online:
- 82 Downloads
Despite remaining the leading cause of preventable death in the United States, tobacco smoking does not garner the attention it deserves in the medical and public health communities. Smoking is often referred to merely as a “bad habit” that simply requires adequate willpower to conquer effectively. Fortunately, recent attitudes regarding smoking, as illustrated by the latest US Public Health Service Clinical Practice Guidelines, call for a “chronic disease model” for treating tobacco dependence. This article underscores the importance of viewing smoking as a chronic disease by illustrating the effects on morbidity and mortality, discussing the relapsing nature of addiction, outlining the need for continuum of care for different “severities” of illness, and describing the latest research regarding effective treatment components. Tobacco dependence treatments are safe, effective, and cost-saving, and their use should be encouraged and covered by health insurance analogous to other chronic conditions.
KeywordsSmoking cessation Tobacco dependence Nicotine replacement Cessation pharmacotherapy Chronic disease model Cardiovascular risk factor
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 1.Fiore MC, Bailey WC, Cohen SJ, et al.: Treating Tobacco Use and Dependence: Clinical Practice Guideline. Rockville, MD: US Department of Health and Human Services. Public Health Service; 2000.Google Scholar
- 2.Heron MP, Hoyert DL, Murphy SL, et al.: Deaths: Final data for 2006. National vital statistics reports; vol 57 no 14. Hyattsville, MD: National Center for Health Statistics; 2009.Google Scholar
- 3.US Department of Health and Human Services: The Consequences of Smoking: A Report of the Surgeon General. Washington DC: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2004.Google Scholar
- 5.Chobanian AV, Bakris GL, Black HR, et al.: National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. JAMA 2003, 289:2560–2572.PubMedCrossRefGoogle Scholar
- 7.National Heart, Lung, and Blood Institute and Boston University: Framingham Heart Study. Available at http://www.framinghamheartstudy.org/risk/coronary.html. Accessed May 7, 2010.
- 8.National Heart, Lung, and Blood Institute: Healthy People 2010 Gateway. Available at http://hp2010.nhlbihin.net/atpiii/calculator.asp?usertype=prof. Accessed May 7, 2010.
- 9.• Steinberg MB, Schmelzer AC, Richardson DL, Foulds J: The case for treating tobacco dependence as a chronic disease. Ann Int Med 2008, 148:554–557. This case study and review demonstrates the benefit of long-term nicotine inhaler use and suggests that tobacco dependence treatment compares favorably to treatment for diabetes across many characteristics. It suggests that tobacco treatments should be reimbursed to the same degree as diabetes.PubMedGoogle Scholar
- 14.• Kahn R, Robertson RM, Smith R, Eddy D: The impact of prevention on reducing the burden of cardiovascular disease. Circulation 2008, 118:576–585. This study evaluated various prevention strategies and concludes that smoking cessation is the only strategy that is cost-saving over 30 years.PubMedCrossRefGoogle Scholar
- 15.•• Fiore MC, Jaén CR, Baker TB, et al.: Treating Tobacco Use and Dependence: 2008 Update. Clinical Practice Guideline. Rockville, MD: U.S. Department of Health and Human Services. Public Health Service; 2008. This clinical practice guideline summarizes the available evidence for several aspects of tobacco dependence treatment including pharmacotherapy, behavioral interventions, and follow-up treatment in various settings.Google Scholar
- 21.The Joint Commission. Screening and Treating Tobacco and Alcohol Use. 2009. Available at http://www.jointcommission.org/PerformanceMeasurement/PerformanceMeasurement/Screening+and+Treating+Tobacco+and+Alcohol+Use.htm. Accessed May 8, 2010.
- 22.Stead LF, Perera R, Bullen C, et al.: Nicotine replacement therapy for smoking cessation. Cochrane Database of Systematic Reviews 2008, 1:CD000146.Google Scholar
- 23.Foulds J, Hughes J, Hyland A, et al.: Barriers to use of FDA-approved smoking cessation medications: implications for policy action. Society for Research on Nicotine and Tobacco and ATTUD. Available at http://www.attud.org/pdf/barriers-smoking-cess-meds.pdf. Accessed May 8, 2010.
- 25.• Schnoll RA, Patterson F, Wileyto EP, et al.: Effectiveness of extended-duration transdermal nicotine therapy. Ann Intern Med 2010, 152:144–151. This randomized trial demonstrates the benefit of longer-term use of the nicotine patch beyond the recommended duration found on the package label. This suggests a need to reconsider the utility of the current labeling for cessation pharmacotherapy, as it appears to be in disagreement with evidence-based data.PubMedGoogle Scholar
- 26.Cummings KM, Hyland A, Giovino GA, et al.: Are smokers adequately informed about the health risks of smoking and medicinal nicotine? Nicotine Tob Res 2004, Suppl 3:S333–340.Google Scholar
- 27.Hyland A: Perceptions of NRT safety and efficacy: results from the International Tobacco Control (ITC) Four C Country Survey. Presented at Society for Research on Nicotine and Tobacco (SRNT) Preconference Symposium, Increasing Access to Effective Treatments: The Case for More Flexible Regulatory Policy. Austin, TX; February 21, 2007. Available at http://roswelldocs.com/srnt.htm
- 31.Brick J: Handbook of the Medical Consequences of Alcohol and Drug Abuse. New York: The Howarth Press; 2008.Google Scholar
- 34.• Shiffman S, Brockwell SE, Pillitteri JL, Gitchell JG: Use of smoking-cessation treatments in the United States. Am J Prev Med 2008, 34:102–111. This population-level study demonstrated that the majority of smokers who report making a quit attempt do so without any behavioral or pharmacologic support.PubMedCrossRefGoogle Scholar
- 35.• Smith SS, Mccarthy DE, Japuntich SJ, et al.: Comparative effectiveness of 5 smoking cessation pharmacotherapies in primary care clinics. Arch Intern Med 2009, 169:2148–2155. This randomized trial adds to the data demonstrating the benefit of combination pharmacotherapy for tobacco treatment.PubMedCrossRefGoogle Scholar
- 36.• Steinberg MB, Greenhaus S, Schmelzer AC, et al.: Triple Combination pharmacotherapy for medically ill smokers. A randomized trial. Ann Intern Med 2009, 150:447–454. This randomized trial is the first to demonstrate the benefit of a three-medication combination for treating tobacco dependence in medically ill smokers.PubMedGoogle Scholar
- 39.• Apelberg BJ, Onicescu G, Avila-Tang E, Samet JM: Estimating the risks and benefits of nicotine replacement therapy for smoking cessation in the United States. Am J Public Health 2010, 100:341–348. This economic model suggests that increased utilization of nicotine replacement medications would significantly reduce premature deaths over a 20-year period.PubMedCrossRefGoogle Scholar